Drugs A-Z Is my price fair? Price changes Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Brand-name drug

Austedo price, strengths & recalls

Brand of deutetrabenazine (generic)

Pharmacies pay $6,981.04 for 28 tablets of Austedo xr once daily, 4 week titration pack, 12 mg / 18 mg / 24 mg / 30 mg pack this week, and from $2,494.20 to $15,076.37 across its 12 priced strengths and forms. Its official label last changed on October 16, 2026.

Medicare price 2027Brand
Pharmacies pay$6,981.04for 28 tablets of xr once daily, 4 week titration pack, 12 mg / 18 mg / 24 mg / 30 mg packNo change in 4 weeks
Fair cash price
$8,038.70
Strengths
12
Makers
1
Updated
Nov 11

Austedo price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
6 mg (24 hr) extended-release tablet Brand$83.14$2,494.20 / 30 tablets+0.1%+4.3%
12 mg (24 hr) extended-release tablet Brand$166.94$5,008.27 / 30 tablets+0.1%+5.5%
18 mg (24 hr) extended-release tablet Brand$251.16$7,534.82 / 30 tabletsNo change+5.3%
24 mg (24 hr) extended-release tablet Brand$250.32$7,509.50 / 30 tablets-0.1%+5.3%
30 mg (24 hr) extended-release tablet Brand$332.41$9,972.32 / 30 tabletsNo change+5.1%
36 mg (24 hr) extended-release tablet Brand$416.58$12,497.47 / 30 tabletsNo change+5.3%
42 mg (24 hr) extended-release tablet Brand$498.72$14,961.53 / 30 tablets+0.1%+5.3%
48 mg (24 hr) extended-release tablet Brand$502.55$15,076.37 / 30 tablets+0.3%+5.9%
Xr once daily, 4 week titration pack, 12 mg / 18 mg / 24 mg / 30 mg pack Brand$249.32$6,981.04 / 28 tabletsNo change
6 mg tablet Brand$83.27$2,498.11 / 30 tablets+0.1%+5.1%
9 mg tablet Brand$93.83$2,814.84 / 30 tablets-0.2%+4.9%
12 mg tablet Brand$125.00$3,750.02 / 30 tabletsNo change+5.2%

The lowest cost per tablet is 6 mg (24 hr) extended-release tablet at $83.14. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.

Austedo vs generic deutetrabenazine

There is no generic version of Austedo on the market yet. Its last listed patent or exclusivity runs to June 10, 2041 - generics often follow, though court cases and settlements can move the date either way.

GenericDeutetrabenazine prices

Medicare negotiated price

$6,623.00$4,093.00-38%

Medicare negotiated a maximum fair price of $4,093.00 for a 30-day supply of Austedo / Austedo XR, against a 2024 list price of $6,623.00. It takes effect on January 1, 2027.

What this means for patients

  • The negotiated price is what Medicare Part D plans pay for the drug - not your price at the counter.
  • What you pay depends on your plan's copay or coinsurance and where you are in the year. Coinsurance (a percentage) falls with the price; a flat copay may not change at all.
  • Out-of-pocket costs for Part D drugs are capped each year ($2,100 in 2026), whatever the drug.
  • If you don't have Medicare, the negotiated price doesn't apply to you - check the fair cash price above instead.
Every Medicare negotiated price

Supply status: shortages & recalls

No shortage reportedChecked Nov 15, 2026
No ongoing recallsNone on record

What did you pay for austedo? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedOctober 16, 2026
Version36 of 26
EffectiveFeb 28, 2025
Read the label

These highlights do not include all the information needed to use AUSTEDO XR or AUSTEDO safely and effectively. See full prescribing information for AUSTEDO XR and AUSTEDO.AUSTEDO XR® (deutetrabenazine) extended-release tablets, for oral use AUSTEDO® (deutetrabenazine) tablets, for oral useInitial U.S. Approval: 2017

This drug has a boxed warning

WARNING: DEPRESSION AND SUICIDALITY IN PATIENTS WITH HUNTINGTON'S DISEASE

AUSTEDO XR and AUSTEDO can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease. Anyone considering the use of AUSTEDO XR or AUSTEDO must balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior. Patients, their caregivers, and families should be informed of the risk of depression and suicidality and should be instructed to report behaviors of concern promptly to the treating physician.

Particular caution should be exercised in treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in Huntington's disease. AUSTEDO XR and AUSTEDO are contraindicated in patients who are suicidal, and in patients with untreated or inadequately treated depression [see Contraindications (4) and Warnings and Precautions (5.1)].

WARNING: DEPRESSION AND SUICIDALITY IN PATIENTS WITH HUNTINGTON'S DISEASE

See full prescribing information for complete boxed warning.

Increases the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease (5.1)

Balance risks of depression and suicidality with the clinical need for treatment of chorea when considering the use of AUSTEDO XR or AUSTEDO (5.1)

Monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior (5.1)

Inform patients, caregivers, and families of the risk of depression and suicidality and instruct to report behaviors of concern promptly to the treating physician (5.1)

Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation (5.1)

AUSTEDO XR and AUSTEDO are contraindicated in patients who are suicidal, and in patients with untreated or inadequately treated depression (4, 5.1)

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Application
NDA216354 · Teva
First approved
February 17, 2023 (3 years ago)
Latest approved change
February 28, 2025
Approved label
PDF, Mar 3, 2025
Generic makers
None on the market
Last patent listed
June 10, 2041

Patent dates are what the maker lists with FDA. Generic launch dates are often set by court rulings or settlements instead. Upcoming generics.

Austedo questions

How much does austedo cost without insurance?

Pharmacies pay about $6,981.04 for 28 tablets of austedo xr once daily, 4 week titration pack, 12 mg / 18 mg / 24 mg / 30 mg pack ($249.32 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $8,038.70. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

Is there a generic for Austedo?

Yes: deutetrabenazine. Compare deutetrabenazine prices.

Is austedo in shortage?

No shortage is reported for austedo right now. We check the national shortage list every day.

Has austedo been recalled?

No recalls are on record for austedo.

When did the austedo label last change?

The official label was last updated on October 16, 2026 (version 36). See what changed.

Does Medicare have a negotiated price for Austedo?

Yes: $4,093.00 for a 30-day supply of Austedo / Austedo XR, from January 1, 2027. What you pay still depends on your plan.

Talk about austedo

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.